Clinical Trial Update: Study Evaluating rhIL-11 in Active Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial of recombinant human interleukin-11 in active Crohn's disease has completed; Wyeth is now a subsidiary of Pfizer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Inflammatory Bowel Disease

Drugs mentioned

• Recombinant Human Interleukin-11 (interleukin-11)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Crohn Disease, Inflammatory Bowel Disease | Phase 2 | Status: COMPLETED